Abstract
Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Current Drug Targets
Title: Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites
Volume: 8 Issue: 1
Author(s): John E. Hyde
Affiliation:
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Abstract: Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Export Options
About this article
Cite this article as:
Hyde E. John, Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315524
DOI https://dx.doi.org/10.2174/138945007779315524 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Improving Safety of Gene Therapy
Current Drug Safety Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Plant Phenolic Compounds as Potential Lead Compounds in Functional Foods for Antiviral Drug Discovery
Current Organic Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches
Infectious Disorders - Drug Targets Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens
Current Drug Metabolism The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry The Role of the Urokinase Receptor in Epilepsy, in Disorders of Language, Cognition, Communication and Behavior, and in the Central Nervous System
Current Pharmaceutical Design An Overview of Acute Flaccid Myelitis
CNS & Neurological Disorders - Drug Targets Pathogen-Related Signal Transduction Pathways of Dendritic Cells: Perspectives for Cancer Immunotherapy
Current Signal Transduction Therapy Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology